FY2026 EPS Estimates for Roche Decreased by Erste Group Bank

Roche Holding AG (OTCMKTS:RHHBY) – Stock analysts at Erste Group Bank dropped their FY2026 EPS estimates for shares of Roche in a note issued to investors on Thursday, April 2nd. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $3.16 for the year, down from their prior estimate of $3.19. The consensus estimate for Roche’s current full-year earnings is $2.81 per share. Erste Group Bank also issued estimates for Roche’s FY2027 earnings at $3.36 EPS.

A number of other research analysts also recently weighed in on the stock. Barclays upgraded shares of Roche from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Zacks Research upgraded shares of Roche from a “strong sell” rating to a “hold” rating in a report on Monday, January 5th. Citigroup began coverage on shares of Roche in a report on Tuesday, January 27th. They issued a “buy” rating on the stock. Wolfe Research reiterated an “outperform” rating on shares of Roche in a report on Thursday, February 26th. Finally, Argus upgraded shares of Roche from a “hold” rating to a “buy” rating in a report on Monday. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $57.00.

Roche Stock Performance

Roche stock opened at $49.35 on Wednesday. The firm’s fifty day simple moving average is $54.45 and its 200-day simple moving average is $50.04. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38. Roche has a 1-year low of $34.75 and a 1-year high of $60.85.

Institutional Trading of Roche

Several hedge funds and other institutional investors have recently bought and sold shares of RHHBY. Curio Wealth LLC acquired a new stake in Roche in the 3rd quarter worth $25,000. Oakworth Capital Inc. acquired a new stake in Roche in the 3rd quarter worth $57,000. Salomon & Ludwin LLC grew its position in Roche by 256.6% in the 3rd quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock worth $129,000 after purchasing an additional 2,053 shares during the last quarter. Atlas Capital Advisors Inc. acquired a new stake in Roche in the 4th quarter worth $192,000. Finally, Douglass Winthrop Advisors LLC acquired a new stake in Roche in the 3rd quarter worth $201,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.